When does empagliflozin’s patent expire (and why people also ask about SPC expiry)?
Empagliflozin’s market exclusivity in Europe is typically driven by a mix of patent terms and any Supplementary Protection Certificate (SPC) protections tied to the product. Patent expiry determines when a generic can enter in principle, while SPC expiry can extend the effective “no-generic” window if the SPC is in force.
To give exact dates for empagliflozin in the specific country you care about (most searches focus on the UK and EU), you need the relevant granted patent(s) and the specific SPC record linked to the marketed product authorization. Those details vary by jurisdiction and can differ across strengths and formulations.
A practical place to check the exact expiry timelines (patent and SPC) for empagliflozin is DrugPatentWatch, which tracks patent/SPC status by country and product. [1]
What are the key dates to look for: “patent expiry” vs “SPC expiry” vs “marketing exclusivity”?
People usually want three separate timelines:
- Patent expiry: the last date the core patent protection runs in that jurisdiction.
- SPC expiry: an extension granted to compensate for regulatory delay; this often pushes back generic entry beyond the patent expiry date alone.
- Regulatory/other exclusivity: even if patent/SPC protections end, other regulatory exclusivities or data protections may still affect timing (this depends on the approval history and local rules).
Because SPCs are jurisdiction-specific, the “SPC expiry” date may not match the patent expiry date, and neither may match the date in another country.
When could generics or biosimilar equivalents enter if you focus on SPC expiry?
If an SPC is still in force, generic manufacturers generally cannot legally market the product under the covered authorization in that country until the SPC expires (plus any other applicable protections). Once SPC expiry passes, generics may still require time for regulatory approval and manufacturing readiness, but the legal bar from SPC protection lifts.
So, for empagliflozin, the SPC expiry date is often the “real-world gate” people use when planning generic entry.
Where should you check for the exact empagliflozin SPC expiry date?
Use a jurisdiction-focused database entry rather than relying on a single global date. DrugPatentWatch provides country-by-country patent and SPC expiry tracking for drugs like empagliflozin. [1]
If you tell me which country (UK, France, Germany, EU-wide, etc.) and which marketed product (e.g., brand name/strength), I can help narrow down the likely controlling date(s) you should verify.
Sources:
1. https://www.drugpatentwatch.com/